Bone Metastasis and the Immunosuppressive Tumor Microenvironment: Mechanisms and Therapeutic Strategies
Abstract
Numerous solid tumours have bone as one of their most common sites of distant metastasis, and bone metastasis causes skeletal-related events (SREs) that impair quality of life and portend poor prognosis. Bone metastasis arises not from invasive tumour cells alone but through mutual adaptation and co-evolution between tumour cells and the bone microenvironment. A key mechanism of immune evasion is the establishment of an immunosuppressive microenvironment, wherein tumour-derived cytokines, metabolic reprogramming, and extracellular vesicles drive M2 macrophage polarization, CD8+ T-cell exhaustion, regulatory T-cell enrichment, and natural killer cell dysfunction. Transforming growth factor-β (TGF-β) released during the “tumour-bone” vicious cycle further amplifies local immunosuppression, and metabolic reprogramming depletes glucose and amino acids while accumulating lactate, directly impairing effector T-cell function. Immune checkpoint inhibitor (ICI) therapy shows limited efficacy in bone metastases; however, combination strategies including bone-protective agents (denosumab, bisphosphonates), metabolic modulators, cytokine- or extracellular vesicle-targeted agents, novel nanodelivery systems, and engineered cell therapies demonstrate encouraging preclinical and early clinical promise for reversing immunosuppression. Translation still faces major challenges, including microenvironmental heterogeneity, a lack of bone-specific biomarkers, combination-related toxicity, and delivery bottlenecks. This review aims to synthesize the mechanisms underlying the immunosuppressive bone-metastasis microenvironment and to appraise current and emerging combination strategies, thereby informing individualized treatment for patients with bone metastases.